KARYOPHARM THERAPEUTICS INC
KPTINASDAQ🏆 #3362 by market capUS Equity
$702.86▼ $45.40 (−6.46%)
Simulated price1h—
24h▼ 6.5%
7d—
14d—
30d—
1y—
🏦Market Cap
$48M
Small Cap
📈Revenue Growth (YoY)
+6.3%
Slowing
📊Gross Margin
96.0%
High
💵FCF Margin
—
⚖️P/S Ratio
0.3x
Cheap
Otter Score
44
Weak
No chart data available for KPTI.
Trading Snapshot
- Day Range
- $699.00 – $709.92
- 52-Week Range
- $1.80 – $10.99
- Volume
- $2.84B
- Avg Volume
- $2.77B
- Shares Outstanding
- 22.7M
- Next Earnings
- Oct 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $150M
- Last Q Revenue
- $34M
- P/E Ratio
- —
- P/S Ratio
- 0.3x
- EPS (TTM)
- $-14.84
- Dividend Yield
- —
Why Investors Own KPTI
- ✓High-growth profile — revenue up +40.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 37% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$150M▲ +36.2% YoY
Gross Margin (TTM)
37.1%▲ +3.5% YoY
Operating Income (TTM)
$33M▲ +36.2% YoY
Free Cash Flow (TTM)
$20M▲ +36.2% YoY
About KARYOPHARM THERAPEUTICS INC
A company profile for KARYOPHARM THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
44/100
Analyst Price Target
ⓘAverage Target
$887.74
▲ +26.3% Upside
High Target$1,113.76
Low Target$674.91
Based on 38 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
KARYOPHARM THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift KPTI price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
KARYOPHARM THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.